The Individual Cell Properties of Oral Squamous Cell Carcinoma and p53 Tumor Suppressor Gene Mutation

Oral Science International

Volumn 2, Issue 2, 2005, Pages 104-117

  Kamiya, Yoko ^a   Ohshima, Tomoko ^a  

^a TSURUMI UNIVERSITY   (Japan)

Author keywords

Anti canser drug susceptibility; Cell invasion activity; Oral squamous cell carcinoma; p53 Tumor suppressor gene

Indexed keywords

EID: 40549134214     PISSN: 13488643     EISSN: None     Source Type: Journal    
DOI: 10.11277/osi.2.104     Document Type: Article

References (37)

1. Soussi T., Dehouche K., and Beroud C: p 53 website and analysis of p 53 gene mutations in human cancer : forging a link between epidemiology and carcinogenesis. Hum Mutat 15 : 105–113, 2000.
2. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., pancosk P., and Moll UM. : p 53 has a direct apoptogenic role at the mitochondria. Mol Cell 11 : 577–590, 2003.
3. Chipuk J. E., Kuwana T., Bouchier-Hayes L., Droin NM., Newmeyer DD., Schuler M., and Green DR. : Direct activation of Bax by p 53 Mediates mitochondrial membrane permeabilization and apoptosis. Science 303 : 1010–1014, 2003.
4. Sudomi T., Hamajima N., Ogawa M., and Takahashi T.: Prognostic significance of p 53 alteration in patients with non-small cell lung cancer : a meta-analysis. Clin Cancer Res 6 : 4055–4063, 2000.
5. Caelles C., Helmberg A., and Karin M.: p 53-dependent apoptosis in the absence of transcriptional activation of p 53-target genes. Nature 370 : 220–223, 1994.
6. Olivier M., Eeles R., Hollstein M., Khan M., Harris C., and Hainaut P.: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19 : 607–614, 2002.
7. Kato S., Han S. Y., Liu W., Otsuka K., Shibata H., and Kanamaru R.: Understanding the function-structure and function-mutation relationships of p 53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100 : 8424–8429, 2003.
8. Ishioka C.: p 53 and human cancer. Kareiigaku Kenkyusho Zassi 56 : 1–34, 2004.
9. Aas T., Borresen A. L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J. E., Akslen L.A., and Lonning P.E.: Specific p 53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med Nat Med 2 : 811–814, 1996.
10. Pergo P., Giarola M., Righetti S. C., Supino R., Caserini C., Delia D., Pierotti M. A., Miyashita T., Reed J.C., and Zumino F.: Association between cisplatin resistance and mutation of p 53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56 : 556–562, 1996.
11. Fan S., el-Diery W. S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A.J. Jr., Magrath I., Kohn K.W., and O'Connor P.M.: p 53 gene mutations are associations with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54 : 5824–5830, 1994.
12. Fan S., Smith M. L., Rivet D. J., Duba D., Zhan Q., Kohn K. W., Fornace A.J. Jr., and O'Connor P.M.: Discription of p 53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55 : 1649–1654, 1995.
13. Wahl A. F., Donaldson K. L., Fairchild C., Lee F.Y.F., Foster S. A., Demers G.W., and Galloway D.A.: Loss of normal p 53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2 : 72–79, 1996.
14. Hawkins D. S., Demers G.W., and Galloway D.A.: Inactivation of p 53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56 : 892–898, 1996.
15. Tada M., Furuuchi K., Kaneda M., Matsumoto J., Takahashi M., Hirai A., Mitsumoto Y., Iggo R.D., and Moriuchi T.: Inactivate the remaining p 53 allele or the alternate p 73? Preferential selection of the Arg72 polymorphism in cancers with recessive p 53 mutants but not transdominant mutants. Carcinogenesis 22 : 515–517, 2001.
16. O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M., Scudiero D. A., Monks A., Sausville E. A., Weinstein J. N., Friend S., Fornace A.J. Jr., and Kohn K.W.: Characterization of the p 53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Canser Res 57 : 4285–4300, 1997.
17. Weinstein J. N., Myerrs T.G., O'Conner P. M., Friend S. H., Fornace A.J. Jr., Kohn K. W., Fojo T., Bates S. E., Rubinstein L. V., Anderson N. L., Buolamwini J.K., van Osdol W. W., Monks A. P., Scudiero D. A., Sausvilla E. A., Zaharevitz D. W., Bunow B., Viswanadhan V. N., Johnson G. S., Wiittes R.E., and Paull K.D.: An information-intensive approach to the molecular pharmacology of cancer. Science 275 : 343–349, 1997.
18. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., Hiller L., Farrell P. J., Smith P., Lu X., and Crook T.: Polymorphism in wild type p 53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 : 3328–3337, 2004.
19. Flores E. R., Tsai K. Y., Crowley D., Sengupta S., Yang A., McKeon F., and Jacks T.: p 63 and p 73 are required for p 53-dependent apoptosis in response to DNA damage. Nature 416 : 560–564, 2002.
20. Albini A., Iwamoto Y., Kleinman H. K., Martin G. R., Aaronson S. A., Kozlowski J.M., and McEwan R.N.: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47 : 3239–3245, 1987.
21. Reprsh L.A.: A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9 : 192–208, 1989.
22. Liotta L.A.: Tumor invasion and metasyases role of the basement membrane. Am J Pathol 117 : 339–348, 1984.
23. Terranova V. P., Hujanen R. S., Loeb D. M., Martin G. R., Thornburg L., and Glushko V.: Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 83 : 465–469, 1986.
24. Ohshima T., Sugawara I., and Fujita H.: The close relationship between the increased p 53 tumor suppressor gene product and expression of multidrug resistance gene (MDR-1). Oral Oncology 4 : 67–70, 1995.
25. Sakai E., and Tsuchida N.: Most human squamous cell carcinoma in the oral cavity contain mutated p 53 tumor-suppressor genes. Oncogene 7 : 927–933, 1992.
26. Matlachewski G. J., Tuck S., Pim D., Lamb P., Schneider J., and Crawford L.V.: Primary structure polymorphism at amino acid residue 72 of human p 53. Mol Cell Biol 7 : 961–963, 1987.
27. Myoung H., Hong S., Yun P., Lee J., and Kim M.: Anticancer effect of genistein in oral squamous cell cartinoma with respect to angiogenesis and in vitro invasion. Cancer Science 94 : 215–220, 2003.
28. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B.: Oncoprotein MDM2 Conceals the activation domain of tumor suppressor p 53. Nature 362 : 857–860, 1993.
29. Lin J., Chen J., Elenbaas B., and Levine A. J.: Several hydrophobic amino acids in the p 53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 the adenovirus 5 E1B 55-kD protein. Genes Dev 8 : 1235–1246, 1994.
30. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole PA., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G., Balsano C., and Levrero M.: DNA damage-dependent acetylation of p 73 dictates the selective activation of apoptotic target genes. Mol Cell 9 : 175–186, 2002.
31. Koushik A., Platt R.W., and Franco E.L.: p 53 codon 72 polymorphism and cervical neoplasia: meta-analysis review. Cancer Epidemiol Biomarkers Prev 13 : 11–22, 2004.
32. Huang X. E., Hamajima N., Katsuda N., Matsuo K., Hirose K., Mizutani M., Iwata H., Miura S., Xiang J., Tokudome S., and Tajima K.: Association of p 53 codon Arg72Pro and p 53 GAC14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese. Breast Cancer 10 : 307–311, 2003.
33. Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutierrez-Enriquez S., Hall J., Guino E., Peinado M. A., Capella G., and Canzian F.: A TP53 polymorphisms is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23 : 1954–1956, 2004.
34. Kuroda Y., Tsukino H., Nakao H., Imai H., and Katoh T.: p 53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189 : 77–83, 2003.
35. Momose F., Araida T., Negishi A., Ichijo H., Sioda S., and Sasaki S.: Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell corcinomas. J Oral Pathol Med 18 : 391–395, 1989.
36. Maria C. M., Christine A. J., Louise A. B., Maredith S. I., Jenny O'Nions, John A. T., Nick J., Jane M. McGregor, Catherine A. H., Isik G. Y., Karen H. V., Martin J. A., Barry G., Shuntar I., Philip W. H., Tiim C., and William G. Kaelin Jr.: A common polymorphism acts as an intragenic modifier of mutant p 53 behaviour. Nature Genet 25 : 47–54, 2000.
37. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., Yulug I., Merlano M., Numico G., Comino A., Attard M., Reelfs O., Gusterson B., Bell A. K., Heath V., Tavassoli M., Farrell P. J., Smith P., Lu X., and Crook T.: polymorphism influences response in cancer chemotherapy via modulation of p 73-dependent apopcosis. Cancer Cell 3 : 387–402, 2003.